

Application Serial No. 10/023,603
Amdt. dated October 22, 2003


Amendments to the Claims

This listing of the claims will replace all prior versions and listing of the claims in the application.

Listing of claims:

Claims 1-3 (cancelled)

Claim 4 (previously presented): A compound of the formula (III.2):



(III.2)

or its pharmaceutically acceptable salt or prodrug thereof, wherein:

Q is CH₂, C(=Z²), S, S(=Z³), (Z³=)S(=Z⁴), PA³, PA³(=O) or P(=O)₂;

Z² is independently O, S or NA⁴;

Z³ and Z⁴ are independently O or NA⁵ wherein Z³ and Z⁴ both cannot be NA⁵;

A³, A⁴ and A⁵ are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkcarbonyl;

A⁷ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic or alkcarbonyl;

R⁶, R⁷, R⁹ and R¹⁰ are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl,

Application Serial No. 10/023,603
Amdt, dated October 22, 2003

hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate; or alternatively

R^6 and R^7 , R^9 and R^{10} , A^7 and $R^{9/10}$, and A^7 and R^6 independently can come together to form a bridged compound comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate;

wherein if A^7 and R^6 independently come together to form a seven-membered bridged compound, then Q cannot be $C(=O)$;

m is 0 or 1;

Y^1 is O, S, NA^8 or $CR^{11}R^{12}$; and

A^8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, or alkcarbonyl;


R^{11} and R^{12} are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate; alternatively

Application Serial No. 10/023,603
Amdt. dated October 22, 2003

R^{11} and R^{12} independently can come together to form a spiro or bridged compound comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate.

Claims 5-9 (cancelled)

Claim 10 (previously presented): A pharmaceutical composition for the treatment or prophylaxis of a disorder mediated by a vasopressin receptor comprising an agonistic or antagonistic effective amount of a compound of the formula (III.2):



(III.2)

or its pharmaceutically acceptable salt or prodrug thereof, wherein:

Q is CH_2 , $C(=Z^2)$, S , $S(=Z^3)$, $(Z^3=)S(=Z^4)$, PA^3 , $PA^3(=O)$ or $P(=O)_2$;

Z^2 is independently O , S or NA^4 ;

Z^3 and Z^4 are independently O or NA^5 wherein Z^3 and Z^4 both cannot be NA^5 ;

A^3 , A^4 and A^5 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkcarbonyl;

Application Serial No. 10/023,603
Amdt. dated October 22, 2003

A^7 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic or alkcarbonyl;

R^6 , R^7 , R^9 and R^{10} are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate; or alternatively

R^6 and R^7 , R^9 and R^{10} , A^7 and $R^{9/10}$, and A^7 and R^6 independently can come together to form a bridged compound comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate;

wherein if A^7 and R^6 independently come together to form a seven-membered bridged compound, then Q cannot be $C(=O)$;

m is 0 or 1;

Y^1 is O, S, NA^8 or $CR^{11}R^{12}$; and

A^8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, or alkcarbonyl;

R^{11} and R^{12} are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic

Application Serial No. 10/023,603
Amdt. dated October 22, 2003


acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate; alternatively

R^{11} and R^{12} independently can come together to form a spiro or bridged compound comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate;

in a pharmaceutically acceptable carrier or diluent.

Claims 11-15 (cancelled)

Claim 16 (previously presented): A pharmaceutical composition for the treatment or prophylaxis of a disorder mediated by a vasopressin receptor comprising an agonistic or antagonistic effective amount of a compound of the formula (III.2):



(III.2)

or its pharmaceutically acceptable salt or prodrug thereof, wherein:

Q is CH_2 , $C(=Z^2)$, S , $S(=Z^3)$, $(Z^3=S(=Z^4))$, PA^3 , $PA^3(=O)$ or $P(=O)_2$;

Z^2 is independently O , S or NA^4 ;

Application Serial No. 10/023,603
Amdt. dated October 22, 2003

Z^3 and Z^4 are independently O or NA^5 wherein Z^3 and Z^4 both cannot be NA^5 ;

A^3 , A^4 and A^5 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkcarbonyl;

A^7 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic or alkcarbonyl;

R^6 , R^7 , R^9 and R^{10} are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate; or alternatively

R^6 and R^7 , R^9 and R^{10} , A^7 and $R^{9/10}$, and A^7 and R^6 independently can come together to form a bridged compound comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate;

wherein if A^7 and R^6 independently come together to form a seven-membered bridged compound, then Q cannot be $C(=O)$;

m is 0 or 1;

Y^1 is O, S, NA^8 or $CR^{11}R^{12}$; and

Application Serial No. 10/023,603
Amdt. dated October 22, 2003

A⁸ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycl alkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, or alkcarbonyl;

R¹¹ and R¹² are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate; alternatively


R¹¹ and R¹² independently can come together to form a spiro or bridged compound comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate;

in combination with one or more other effective vasopressin receptor agonists or antagonists, optionally in a pharmaceutically acceptable carrier or diluent.

Claims 17-21 (cancelled)

Application Serial No. 10/023,603
Amdt. dated October 22, 2003

Claim 22 (previously presented): A method for the treatment or prophylaxis of a disorder mediated by the vasopressin receptor comprising administering an agonistic or antagonistic effective amount of a compound of the formula (III.2):



(III.2)

or its pharmaceutically acceptable salt or prodrug thereof, wherein:

Q is CH_2 , $\text{C}(=\text{Z}^2)$, S, $\text{S}(=\text{Z}^3)$, $(\text{Z}^3=\text{S}(=\text{Z}^4))$, PA^3 , $\text{PA}^3(=\text{O})$ or $\text{P}(=\text{O})_2$;

Z^2 is independently O, S or NA^4 ;

Z^3 and Z^4 are independently O or NA^5 wherein Z^3 and Z^4 both cannot be NA^5 ;

A^3 , A^4 and A^5 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkcarbonyl;

A^7 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic or alkcarbonyl;

R^6 , R^7 , R^9 and R^{10} are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate; or alternatively

Application Serial No. 10/023,603
Amdt. dated October 22, 2003

R^6 and R^7 , R^9 and R^{10} , A^7 and $R^{9/10}$, and A^7 and R^6 independently can come together to form a bridged compound comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate;

wherein if A^7 and R^6 independently come together to form a seven-membered bridged compound, then Q cannot be C(=O);

m is 0 or 1;

Y^1 is O, S, NA^8 or $CR^{11}R^{12}$; and

A^8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, or alkcarbonyl;

R^{11} and R^{12} are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate; alternatively

R^{11} and R^{12} independently can come together to form a spiro or bridged compound comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide,


Application Serial No. 10/023,603
Amdt. dated October 22, 2003

anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate;

optionally in a pharmaceutically acceptable carrier or diluent.

Claims 23-27 (cancelled)

Claim 28 (currently amended): A method for the treatment or prophylaxis of a disorder mediated by the vasopressin receptor comprising administering an agonistic or antagonistic effective amount of a compound of the formula (III.2):



(III.2)

or its pharmaceutically acceptable salt or prodrug thereof, wherein Q, A⁷, R⁶, R⁷, R⁹ and R¹⁰ are defined above;

Q is CH₂, C(=Z²), S, S(=Z³), (Z³)S(=Z⁴), PA³, PA³(=O) or P(=O)₂;

Z² is independently O, S or NA⁴;

Z³ and Z⁴ are independently O or NA⁵ wherein Z³ and Z⁴ both cannot be NA⁵;

A³, A⁴ and A⁵ are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkcarbonyl;

A⁷ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic or alkcarbonyl;

R⁶, R⁷, R⁹ and R¹⁰ are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl,

Application Serial No. 10/023,603
Amdt. dated October 22, 2003

hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate; or alternatively

R^6 and R^7 , R^9 and R^{10} , A^7 and $R^{9/10}$, and A^7 and R^6 independently can come together to form a bridged compound comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate;

wherein if A^7 and R^6 independently come together to form a seven-membered bridged compound, then Q cannot be $C(=O)$;

m is 0 or 1;

Y^1 is O, S, NA^8 or $CR^{11}R^{12}$; and

A^8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, or alkcarbonyl;

R^{11} and R^{12} are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate; alternatively

Application Serial No. 10/023,603
Amdt. dated October 22, 2003

R^{11} and R^{12} independently can come together to form a spiro or bridged compound comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaromatic, alkoxy, amino, halogen, silyl, thiol, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, hydroxyl, ester, alkcarbonyl, carbonyl, acyl, thioester, acid halide, carboxylic acid, amide, imine, nitro, cyano, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, acid halide, anhydride, oxime, hydrazine, carbamate, thioether anhydride, residue of a natural or synthetic amino acid, or carbohydrate;

in combination or alternation with one or more other effective vasopressin receptor agonists or antagonists, optionally in a pharmaceutically acceptable carrier or diluent.

Claims 29-30 (cancelled).

Claim 31 (previously presented): The method of claim 22 or 28, wherein the disorder mediated by the vasopressin receptor is renal dysfunction.

Claim 32 (previously presented): The method of claim 22 or 28, wherein the disorder mediated by the vasopressin receptor is hypertension.

Claim 33 (previously presented): The method of claim 22 or 28, wherein the host is a human.

Claim 34 (previously presented): The compound of claim 4, wherein Q is $(Z^3=)S(=Z^4)$, and Z^3 and Z^4 are O.

Claim 35 (previously presented): The compound of claim 4, wherein $Y^1=NA^8$ and A^8 is H or alkyl.

Claim 36 (previously presented): The compound of claim 4, wherein A^7 is H or alkyl.

Claim 37 (previously presented): The compound of claim 4, wherein R^6 is H, and R^7 is H or alkoxy.

Claim 38 (previously presented): The compound of claim 4, wherein R^9 is H or alkoxy.

Application Serial No. 10/023,603
Amdt. dated October 22, 2003

Claim 39 (previously presented): The compound of claim 4, wherein R^{10} is amide or carbonyl.

Claim 40 (previously presented): The compound of claim 4, wherein

Q is $(Z^3=)S(=Z^4)$, and Z^3 and Z^4 are O;

$Y^1=NA^8$ and A^8 is H or alkyl;


A^7 is H or alkyl;

R^6 is H and R^7 is H or alkoxy;

R^9 is H or alkoxy; and

R^{10} is amide or carbonyl.

Claim 41 (previously presented): The compound of claim 4, wherein the compound is:



Claim 42 (previously presented): The composition of claim 10 or 16, wherein Q is $(Z^3=)S(=Z^4)$, and Z^3 and Z^4 are O.


Claim 43 (previously presented): The composition of claim 10 or 16, wherein $Y^1=NA^8$ and A^8 is H or alkyl.

Claim 44 (previously presented): The composition of claim 10 or 16, wherein A^7 is H or alkyl.

Claim 45 (previously presented): The composition of claim 10 or 16, wherein R^6 is H, and R^7 is H or alkoxy.

Application Serial No. 10/023,603
Amdt. dated October 22, 2003

- Claim 46 (previously presented): The composition of claim 10 or 16, wherein R^9 is H or alkoxy.
- Claim 47 (previously presented): The composition of claim 10 or 16, wherein R^{10} is amide or carbonyl.
- Claim 48 (previously presented): The composition of claim 10 or 16, wherein
 Q is $(Z^3=S(=Z^4))$, and Z^3 and Z^4 are O;
 $Y^1=NA^8$ and A^8 is H or alkyl;
 A^7 is H or alkyl;
 R^6 is H and R^7 is H or alkoxy;
 R^9 is H or alkoxy; and
 R^{10} is amide or carbonyl.
- Claim 49 (previously presented): The composition of claim 10 or 16, wherein the compound is:



- Claim 50 (previously presented): The method of claim 22 or 28, wherein Q is $(Z^3=S(=Z^4))$, and Z^3 and Z^4 are O.
- Claim 51 (previously presented): The method of claim 22 or 28, wherein $Y^1=NA^8$ and A^8 is H or alkyl.
- Claim 52 (previously presented): The method of claim 22 or 28, wherein A^7 is H or alkyl.

Application Serial No. 10/023,603
Amdt. dated October 22, 2003

Claim 53 (previously presented): The method of claim 22 or 28, wherein R^6 is H, and R^7 is H or alkoxy.

Claim 54 (previously presented): The method of claim 22 or 28, wherein R^9 is H or alkoxy.

Claim 55 (previously presented): The method of claim 22 or 28, wherein R^{10} is amide or carbonyl.

Claim 56 (previously presented): The method of claim 22 or 28, wherein

Q is $(Z^3)S(=Z^4)$, and Z^3 and Z^4 are O;

$Y^1=NA^8$ and A^8 is H or alkyl;

A^7 is H or alkyl;

R^6 is H and R^7 is H or alkoxy;

R^9 is H or alkoxy; and

R^{10} is amide or carbonyl.

Claim 57 (previously presented): The method of claim 22 or 28, wherein the compound is:

